Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
about
Emerging importance of ALK in neuroblastomaSafety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.Protein glycosylation in cancers and its potential therapeutic applications in neuroblastomaThe zebrafish as a model for studying neuroblastomaMolecular pathogenesis of peripheral neuroblastic tumorsOverview and recent advances in the treatment of neuroblastoma.Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosineNew aspects of neuroblastoma treatment: ASPHO 2011 symposium reviewWild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cellsInhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomasNeuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.Cooperative Cross-Talk between Neuroblastoma Subtypes Confers Resistance to Anaplastic Lymphoma Kinase Inhibition.Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastomaThe role of intracellular calcium for the development and treatment of neuroblastoma.Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications.In search of targeted therapies for childhood cancer.Promising therapeutic targets in neuroblastomaMolecular profiling of childhood cancer: Biomarkers and novel therapiesAlternative transcription initiation leads to expression of a novel ALK isoform in cancer.Targeting ALK in neuroblastoma--preclinical and clinical advancements.Cell survival signaling in neuroblastoma.ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.The connections between neural crest development and neuroblastoma.Cytokines in neuroblastoma: from pathogenesis to treatment.New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.Preclinical drug development for childhood cancer.Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.New insights into the genetics of neuroblastoma.Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.New immunotherapeutic strategies for the treatment of neuroblastoma.Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.
P2860
Q26858819-A5B2CF7A-D46E-4F0D-936E-F3E695C7DF1FQ27852211-C95C9EA4-8BE5-4F1C-9AAC-BA06F7BECEEDQ27853323-2452C7FE-00EE-420C-9354-7EE696C04066Q28069952-9EA8CA8A-D806-4DE4-8359-57FFDE6C8D08Q28070309-50ADE4AD-5293-4CC3-BFE0-522AC851A117Q28271405-D5F1D7F9-6A1E-4A44-A966-858485058EBBQ30238693-E3E50066-E339-42E7-B1E6-667263AE1A20Q33659849-986296DE-D0E5-4918-8911-B9D39A0668E1Q33721880-605C422A-B09D-4C32-8E35-930468A91662Q33888833-FD2F82A5-4DA2-48C7-AE42-AF7897FBC39BQ33922797-EDA81CB4-664D-4F09-A121-3C6C5D41C1F5Q34101007-C296012F-F9AF-4D72-851E-B8F66623BCA4Q34109019-31F0AE3F-9D6A-4485-BB23-BCDE7478669FQ34134105-A6C7B31A-829D-4AE2-8EE0-9C26F9A18C54Q35086721-359A926D-A0D8-4FB7-A8C1-B76FE00CDBE1Q35180335-07053BC7-CDB6-4B42-9F81-970CE4DE7807Q35623435-726553EF-D757-4FBE-B905-D15BCD58710EQ35818437-DFA73F0A-8E40-4A68-AD8F-6EAFD28635DAQ35818443-64812E28-CFCF-421C-8BA2-6F2928FA7FC0Q35971733-96F1764A-6EEE-4739-B17D-BBF17E9A7D5CQ36055313-0FCEA941-A712-4AC1-A1A1-A15207A9B106Q36250783-6C78AB3E-F7CF-465F-A93C-6DFF9A14BE94Q36726792-C090D7C8-4637-4733-BE89-1E99EC23604DQ36933081-426F1963-BC39-4189-88D1-5E8ABB75F875Q37010166-9BAA5F0E-9D70-4AE9-847B-B10D65681A89Q37154010-7E99C0E9-6979-4D4E-861B-81399BCBD2F7Q37405597-C1BB9604-A59F-4789-9FF0-45C741A76826Q37699419-E30B5FBD-FDEF-46AC-9E4C-589A31158906Q37836006-21E23A08-2FB4-4D9A-B556-9D56099DA034Q37900650-20CFA5F8-F7C0-4804-BAC1-18F86F694E54Q37936432-264A306E-6D70-4813-A294-CA2338128169Q38014543-9B1863F5-8DA4-4D06-A72C-E1281EB41210Q38042570-C711F277-82E6-4985-B2F2-4654634409E5Q38070334-D9843544-0D82-49D0-B916-35DBA2B32E2DQ38074875-4B25E646-B40C-4FAF-941A-BEA109BB4935Q38259956-96E3084E-DEFA-4CC5-B42E-C7EAF44EC7D2Q38389316-6F1B2927-7A30-4ABF-9E42-EAB94FB1034FQ38616826-EA2A7550-8A12-49EB-B83A-DBCDDBD7D4EBQ38694036-3C8C105F-EB93-44E1-894F-AB0DA28A3503Q38806238-E62081D7-13B3-4EBA-ABFF-04A6F4681344
P2860
Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Mutation-independent anaplasti ...... gnosis neuroblastoma patients.
@en
Mutation-independent anaplasti ...... gnosis neuroblastoma patients.
@nl
type
label
Mutation-independent anaplasti ...... gnosis neuroblastoma patients.
@en
Mutation-independent anaplasti ...... gnosis neuroblastoma patients.
@nl
prefLabel
Mutation-independent anaplasti ...... gnosis neuroblastoma patients.
@en
Mutation-independent anaplasti ...... gnosis neuroblastoma patients.
@nl
P2093
P50
P1433
P1476
Mutation-independent anaplasti ...... gnosis neuroblastoma patients.
@en
P2093
Addolorata Maria Luce Coluccia
Andrea Gregorio
Claudio Gambini
Federica Del Grosso
Franca Fossati-Bellani
Gian Paolo Tonini
Mangeng Cheng
Vito Pistoia
P304
P356
10.1158/0008-5472.CAN-08-4419
P407
P50
P577
2009-09-01T00:00:00Z